Page 25 - TD-2-2

Tumor Discovery Practice and consideration of master protocol design

38. CONFIRM: Magnetic Resonance Guided Radiation Therapy A randomized controlled trial. CMAJ, 194(7): E242–E251.
(CONFIRM). Available from: https://clinicaltrials.gov/ct2/ 50. Ader F, Discovery French Trial Management Team, 2020,
show/nct04368702?term=nct04368702&draw=2&rank=1 Protocol for the DisCoVeRy trial: Multicentre, adaptive,
[Last accessed on 2023 Apr 26].
randomised trial of the safety and efficacy of treatments for
39. Walls GM, Oughton JB, Chalmers AJ, et al., 2020, COVID-19 in hospitalised adults. BMJ Open, 10(9): e041437.
CONCORDE: A phase I platform study of novel agents in 51. Bateman RJ, Benzinger TL, Berry S, et al., 2017, The
combination with conventional radiotherapy in non-small- DIAN-TU next generation Alzheimer’s prevention trial:
cell lung cancer. Clin Transl Radiat Oncol, 25: 61–66.
Adaptive design and disease progression model. Alzheimers
40. RECOVERY Collaborative Group, 2020, Lopinavir- Dement, 13(1): 8–19.
ritonavir in patients admitted to hospital with COVID-19 52. Kidwell KM, Roychoudhury S, Wendelberger B, et al., 2022,
(RECOVERY): A randomised, controlled, open-label, Application of Bayesian methods to accelerate rare disease
platform trial. Lancet, 396(10259): 1345–1352.
drug development: Scopes and hurdles. Orphanet J Rare Dis,
41. Yu LM, Bafadhel M, Dorward J, et al., 2021, Inhaled 17(1): 186.
budesonide for COVID-19 in people at high risk of 53. Bertolet M, Brooks MM, Ragni MV, 2020, The design of a
complications in the community in the UK (PRINCIPLE): Bayesian platform trial to prevent and eradicate inhibitors
A randomised, controlled, open-label, adaptive platform in patients with hemophilia. Blood Adv, 4(21): 5433–5441.
trial. Lancet, 398(10303): 843–855.
54. Angus DC, Berry S, Lewis RJ, et al., 2020, The REMAP-CAP
42. Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al., (randomized embedded multifactorial adaptive platform
2022, Effect of early treatment with fluvoxamine on risk of for community-acquired pneumonia) study. Rationale and
emergency care and hospitalisation among patients with design. Ann Am Thorac Soc, 17(7): 879–891.
COVID-19: The TOGETHER randomised, platform clinical
trial. Lancet Global Health, 10(1): e42–e51. 55. Zhai X, Wang X, Wang L, et al., 2020, Treating different
diseases with the same method-a traditional Chinese
43. Huang DT, McCreary EK, Bariola JR, et al., 2021, The medicine concept analyzed for its biological basis. Front
UPMC OPTIMISE-C19 (OPtimizing Treatment and
Impact of Monoclonal antIbodieS through Evaluation for Pharmacol, 11: 946.
COVID-19) trial: A structured summary of a study protocol 56. Jiang M, Zhang C, Zheng G, et al., 2012, Traditional chinese
for an open-label, pragmatic, comparative effectiveness medicine zheng in the era of evidence-based medicine:
platform trial with response-adaptive randomization. Trials, A literature analysis. Evid Based Complement Alternat Med,
22(1): 363. 2012: 409568.
44. LaVange L, Adam SJ, Currier JS, et al., 2021, Accelerating 57. Liu W, Zhou L, Feng L, et al., 2021, BuqiTongluo granule for
COVID-19 therapeutic interventions and vaccines ischemic stroke, stable angina pectoris, diabetic peripheral
(ACTIV): Designing master protocols for evaluation neuropathy with qi deficiency and blood stasis syndrome:
of candidate COVID-19 therapeutics. Ann Intern Med, Rationale and novel basket design. Front Pharmacol,
174(9): 1293–1300. 12: 764669.
45. Beigel JH, Tomashek KM, Dodd LE, et al., 2020, Remdesivir 58. Yuan B, 2021, Towards a clinical efficacy evaluation system
for the treatment of Covid-19-final report. N Engl J Med, adapted for personalized medicine. Pharmgenomics Pers
383(19): 1813–1826. Med, 14: 487–496.
46. Kalil AC, Mehta AK, Patterson TF, et al., 2021, Efficacy 59. De Benedetti F, Gattorno M, Anton J, et al., 2018,
of interferon beta-1a plus remdesivir compared with Canakinumab for the treatment of autoinflammatory
remdesivir alone in hospitalised adults with COVID-19: recurrent fever syndromes. N Engl J Med, 378(20): 1908–1919.
A double-bind, randomised, placebo-controlled, phase 3 60. Doernberg SB, Komarow L, Tran TTT, et al., 2020,
trial. Lancet Respir Med, 9(12): 1365–1376.
Simultaneous evaluation of diagnostic assays for pharyngeal
47. Kalil AC, Patterson TF, Mehta AK, et al., 2021, Baricitinib and rectal neisseria gonorrhoeae and chlamydia trachomatis
plus remdesivir for hospitalized adults with Covid-19. using a master protocol. Clin Infect Dis, 71(9): 2314–2322.
N Engl J Med, 384(9): 795–807.
61. Reitz KM, Seymour CW, Vates J, et al., 2020, Strategies to
48. Wolfe CR, Tomashek KM, Patterson TF, et al., 2022, promote ResiliencY (SPRY): A randomised embedded
Baricitinib versus dexamethasone for adults hospitalised multifactorial adaptative platform (REMAP) clinical trial
with COVID-19 (ACTT-4): A randomised, double- protocol to study interventions to improve recovery after
blind, double placebo-controlled trial. Lancet Respir Med, surgery in high-risk patients. BMJ Open, 10(9): e037690.
10(9): 888–899. 62. Howard DR, Brown JM, Todd S, et al., 2018,
49. Ali K, Azher T, Baqi M, et al., 2022, Remdesivir for the Recommendations on multiple testing adjustment in multi-
treatment of patients in hospital with COVID-19 in Canada: arm trials with a shared control group. Stat Methods Med

Volume 2 Issue 2 (2023) 19 https://doi.org/10.36922/td.342